Sutro Biopharma (STRO) Capital Expenditures (2017 - 2025)

Sutro Biopharma has reported Capital Expenditures for 9 years, with the latest figure at $184000.0 in Q4 2025.

• Quarterly Capital Expenditures fell 92.4% year-over-year to $184000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (down 45.29% YoY) and the FY2025 annual result came in at $1.7 million, down 45.29% from the prior year.
• Capital Expenditures declined to $184000.0 in Q4 2025 per STRO's latest filing, from $1.5 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $13.2 million in Q4 2021 and troughed at -$2.2 million in Q3 2023.
• A 5-year average of $1.0 million and a median of $661500.0 in 2021 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures slumped 350.7% in 2022, then soared 2243.36% in 2024.
• Over 5 years, Capital Expenditures stood at $13.2 million in 2021, then tumbled by 111.36% to -$1.5 million in 2022, then surged by 92.44% to -$113000.0 in 2023, then jumped by 2243.36% to $2.4 million in 2024, then slumped by 92.4% to $184000.0 in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered $184000.0, $1.5 million, and -$4000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.